Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor
All patients were either obese or overweight and had a history of heart disease
Your eating habits could use an upgrade If youre eating a lot of processed, fried, or fatty foods, that could explain why youre not losing weight on semaglutide
Conclusion Understanding the shelf life and proper storage of compounded semaglutide is essential for anyone using this medication as part of their weight loss or diabetes management journey
These are signals, not definitive conclusionsbut they come directly from patients and may deserve further attention, said lead author Neil Sehgal